Ohio State University

1. Novartis Pharmaceuticals Corporation $15,878,103 57 payments
2. AbbVie, Inc. $11,934,540 709 payments
3. Medtronic, Inc. $2,599,286 423 payments
4. E.R. Squibb & Sons, L.L.C. $1,853,727 46 payments
5. Janssen Research & Development, LLC $1,446,969 190 payments
6. Pharmacyclics LLC, An AbbVie Company $1,170,345 251 payments
7. Allergan Inc. $1,139,634 177 payments
8. Sanofi US Services Inc. $1,072,232 17 payments
9. Pfizer Inc. $1,024,582 43 payments
10. Merck Sharp & Dohme Corporation $948,480 16 payments

1. Inflammation Modification to Prevent Leukemic Progression of Clonal Cytopenias of Unknown Signicance Trial (IMPACT) $14,841,376 3 payments
2. Phase 2 study of Venetoclax Added to Ibrutinib to Eliminate Ibrutinib Resistance Mutations in CLL $4,008,682 29 payments
3. A16-555 $2,117,217 42 payments
4. A16-555 $2,028,340 19 payments
5. Pooled Study for Isatuximab $915,647 14 payments
6. Phase III NSCLC 1L, sq anti-PD-1 vs platinum doublet PDL-1 $678,578 3 payments
7. A Phase II trial of the efficacy and safety of the combination of Cemiplimab and Low-dose Paclitaxel and Carboplatin in Patients with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck $598,797 16 payments
8. Cochlear implantation during vestibular schwannoma removal or during labyrinthectomy surgery for the treatment of Menier's disease $546,749 12 payments
9. A Phase 2 Multicohort Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against BCMA in Subjects with Multiple Myeloma $496,434 72 payments
10. Phase 2 Randomized Open-label Multicenter Study of Combination of ONC-392 and Pembrolizumab for the Treatment of Patients with Platinum Resistant Ovarian Cancer PROC $433,400 2 payments

1. Other $214,983 11 payments
2. Patient care $68,897 2 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.